Jazz Pharmaceuticals sold a priority review voucher to an undisclosed buyer for $200 million, the highest reported price for such a voucher since 2016. Jazz will receive half the proceeds and the transaction represents a meaningful non‑dilutive monetization of regulatory assets for the company. Priority review vouchers (PRVs) provide expedited FDA review for a future NDA/BLA and remain a liquid asset in biopharma dealmaking. For corporate and financing teams, the sale underscores the continued secondary market value of regulatory accelerators and may prompt other companies with PRVs to consider similar transactions for balance‑sheet optimization.